Toxicity
| Toxicity CTCAE ver. 3.0 . | R-CHOP (N = 213) . | RW-CHOP (N = 208) . | ||
|---|---|---|---|---|
| Any grade (%) . | Grade 3-4 (%) . | Any grade (%) . | Grade 3-4 (%) . | |
| Leukocytes | 99.5 | 94.4 | 99 | 95.2 |
| ANC | 100 | 97.7 | 99 | 97.1 |
| Platelets | 71.4 | 8 | 74 | 5.3 |
| AST | 67.6 | 1.4 | 71.2 | 2.4 |
| ALT | 60.6 | 3.8 | 65.4 | 5.8 |
| Creatinine | 30 | 0.5 | 28.4 | 0 |
| Hyponatremia | 60.1 | 5.2 | 63.9 | 5.3 |
| Hypokalemia | 35.7 | 3.3 | 37 | 1.9 |
| Hyperglycemia | 90 | 3.8 | 89.4 | 5.3 |
| Cardiac ischemia/infarction | 1.4 | 1.4 | 0.5 | 0.5 |
| LV systolic dysfunction | 12.2 | 0.9 | 14.4 | 1.4 |
| Ileus | 3.8 | 0.9 | 1.4 | 1 |
| Febrile neutropenia | — | 33.8 | — | 22.1 |
| Herpes zoster infection | — | 0.9 | — | 1.9 |
| Neuropathy-sensory | 78.4 | 2.3 | 79.8 | 5.8 |
| Neuropathy-motor | 13.1 | 3.3 | 12 | 2.9 |
| Second primary neoplasms | n = 21* | n = 18 | ||
| Toxicity CTCAE ver. 3.0 . | R-CHOP (N = 213) . | RW-CHOP (N = 208) . | ||
|---|---|---|---|---|
| Any grade (%) . | Grade 3-4 (%) . | Any grade (%) . | Grade 3-4 (%) . | |
| Leukocytes | 99.5 | 94.4 | 99 | 95.2 |
| ANC | 100 | 97.7 | 99 | 97.1 |
| Platelets | 71.4 | 8 | 74 | 5.3 |
| AST | 67.6 | 1.4 | 71.2 | 2.4 |
| ALT | 60.6 | 3.8 | 65.4 | 5.8 |
| Creatinine | 30 | 0.5 | 28.4 | 0 |
| Hyponatremia | 60.1 | 5.2 | 63.9 | 5.3 |
| Hypokalemia | 35.7 | 3.3 | 37 | 1.9 |
| Hyperglycemia | 90 | 3.8 | 89.4 | 5.3 |
| Cardiac ischemia/infarction | 1.4 | 1.4 | 0.5 | 0.5 |
| LV systolic dysfunction | 12.2 | 0.9 | 14.4 | 1.4 |
| Ileus | 3.8 | 0.9 | 1.4 | 1 |
| Febrile neutropenia | — | 33.8 | — | 22.1 |
| Herpes zoster infection | — | 0.9 | — | 1.9 |
| Neuropathy-sensory | 78.4 | 2.3 | 79.8 | 5.8 |
| Neuropathy-motor | 13.1 | 3.3 | 12 | 2.9 |
| Second primary neoplasms | n = 21* | n = 18 | ||
—, corresponding grade is not defined in CTCAE; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; LV, left ventricular; ver., version.
*Including duplicates; 1 patient was diagnosed with papillary adenocarcinoma of thyroid and bladder cancer.